HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.
Vaccine Research and Development
WHO starts initiative for Vaccine Research that facilitates research and development (R&D) against microorganisms with significant economic burden and disease, with a particular focus on low and middle income countries. Our activities span the following areas:
- Facilitation of early stage R&D in disease areas with no available vaccines or sub-optimal vaccines
- Research to optimize public health impact where existing vaccines are underutilized,
- Research to aid introduction decision-making and post-licensure assessments of risk/benefit
- Research to improve monitoring and evaluation of vaccines in use in immunization.
In the past days, the process of vaccine development occur through a series of steps that take a long period of time or many years. Now, in given the urgent need for COVID-19 vaccines, uncommon financial investments and scientific collaborations are changing how vaccines are developed.
Committee Members
Khursheed Anwer
IMUNON, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India IVC 2025 Speakers
Khursheed Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Lara Isis Teodoro
Mayo Clinic, United States
Ahmed Abdulazeez
BHRUT Trust, United KingdomSubmit your abstract Today
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria